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Many patients are dissatisﬁed with scars on both visible and non-visible body sites and would value any opportunity to improve
or minimise scarring following surgery. Approximately 44 million procedures in the US and 42 million procedures in the EU
per annum could beneﬁt from scar reduction therapy. A wide range of non-invasive and invasive techniques have been used in
an attempt to improve scarring although robust, prospective clinical trials to support the eﬃcacy of these therapies are lacking.
Diﬀerences in wound healing and scar outcome between early fetal and adult wounds led to interest in the role of the TGFβ family
of cytokines in scar formation and the identiﬁcation of TGFβ3 (avotermin) as a potential therapeutic agent for the improvement
of scar appearance. Extensive pre-clinical and human Phase I and II clinical trial programmes have conﬁrmed the scar improving
eﬃcacy of avotermin which produces macroscopic and histological improvements in scar architecture, with improved restitution
of the epidermis and an organisation of dermal extracellular matrix that more closely resembles normal skin. Avotermin is safe
and well tolerated and is currently in Phase III of clinical development, with the ﬁrst study, in patients undergoing scar revision
surgery, fully recruited.
1. There Is a MedicalNeed for Therapies That
Reduce Scarringfollowing Surgery
A recent survey performed in the USA conﬁrmed that many
patients are disappointed with their scar resulting from a
surgical procedure, irrespective of gender, age or ethnicity
[1].Understandably,patientsareveryconsciousaboutvisible
scars. However, the survey showed that it is not only visible
scars that cause dissatisfaction, with many patients reporting
scars on nonvisible body sites that they wished were less
noticeable [1]. A patient’s perception of the severity of their
scar can be inﬂuenced not only by the objective appearance
of the scar, but also by other factors including the surgical
technique used and the patient’s sensitivity to the resulting
scar [1, 2]. Many patients would value any opportunity
to improve or minimise scarring following surgery [1].
Indeed it was estimated that there are approximately 44
million procedures performed in the US (Independent
research: Mattson Jack Group) and approximately 42 million
procedures performed in the EU per annum (Independent
research for Renovo: MedTech Insights and TforG) that
could beneﬁt from scar reduction therapy.
2. CurrentTreatments for Scar Management
Are Unsatisfactory
The optimal outcome of wound repair following trauma,
injury or surgery is complete restoration of normal skin.
However, adult wound healing has evolved to rapidly replace
missing tissue with repaired tissue, consisting predominantly
ofﬁbronectinandcollagentypesIandIII.Therepairedtissue
provides an immediate barrier to foreign bodies and infec-
tious agents, irrespective of optimal function or appearance
[3]. However, in the context of modern surgery, which is
performed under sterile conditions, this immediate barrier
is unnecessary and therefore scarring can be considered an
inappropriate response. Furthermore, dermal scarring can2 Dermatology Research and Practice
Table 1: Commonly used approaches to manage scarring post
surgery.
Approaches currently used to manage scarring post-surgery
Non-invasive Invasive
Silicone gel sheeting Steroid injections
Pressure garments Lasers
Hydrating creams/ointments Dermabrasion
Scar-revision surgery
have signiﬁcant adverse consequences including restriction
of movement and psychological trauma.
An u m b e ro fd i ﬀerent approaches have been used in
an eﬀort to manage scarring post surgery ranging from
noninvasive (silicone gel sheeting, pressure garments,
hydrating creams, and ointments) to invasive (steroid
injections, lasers, dermabrasion, and surgery) techniques
[4–9]( Table 1). Unfortunately, many of these approaches are
uncomfortable or burdensome for the patients, and many
require a high level of patient compliance. Furthermore,
prospective, robust clinical trials to demonstrate the eﬃcacy
of scar therapies are lacking, with the majority of published
studies providing only level 4 evidence [10]. Without
clear deﬁnitions of criteria for scar improvement, coupled
with the heterogenous nature of scars themselves, it is
diﬃcult to interpret and compare data from these studies.
Consequently, no single treatment or regimen has been
universally adopted as the standard of care to manage
scarring post surgery. The high level of dissatisfaction
with scar therapies among patients is reﬂected by the high
number of patients who undergo scar revision surgery,
estimated to be over 150,000 per annum in the USA
(http://www.yourplasticsurgeryguide.com/trends/asps-2007
.htm). Indeed many more patients are believed to request
scar revision surgery but are refused as the clinician believes
improvement is unlikely with surgery alone.
3.New Biological ApproachesArein
Development for the Prophylactic
Improvement of Scarring
Anincreaseinourunderstandingoftheprocessesinvolvedin
scarring at the molecular, cellular, and tissue levels has facil-
itated the development of new pharmaceutical approaches
to prevent or treat scarring. While the majority of these
approachesarestillbeinginvestigatedinthelaboratory,afew
haveprogressedtohumanclinicaltrials(Table 2)[9].Todate
thereisnoapprovedpharmaceuticalproductintheUSorthe
EU indicated for the reduction, improvement, or prevention
of dermal scarring.
3.1. The TGFβ Isoforms Play a Key Role in Scar Formation.
Scarring in adult skin is a macroscopic disturbance of the
normal structure and function of the skin architecture that
results from a healed wound [11], although the severity
of the resulting scars diﬀers between people and body
locations. By contrast, skin wounds on early mammalian
embryos have been shown to heal perfectly with no signs
of scarring. The transition between scar-free healing (e.g.,
in early embryonic wounds), to scar-forming healing, (e.g.,
in adults) is characterised by a change in the organisation
of the dermal extracellular matrix from a normal basket
weaveorientationtothedepositionofparallelbundlesofﬁne
collagen ﬁbres that form a scar [11].
There are a large number of diﬀerences between early
fetal and adult wounds, the majority of which appear to be
irrelevant to healing and scar formation. However, much
eﬀort has gone into identifying factors that play a causative
role in the scar-free healing phenotype [12].
In particular, the Transforming Growth Factor beta
(TGFβ) isoforms have been shown to play a key role in
determining the scarring outcome. The high ratio of TGFβ3
to TGFβ1a n dβ2 in embryonic wounds that heal without
a scar compared with adult wounds that scar [13], led
to interest in the role of this family of cytokines in scar
formation. More recently, a signiﬁcantly higher ratio of
TGFβ3 to the other TGFβ isoforms has been shown in
the adult oral mucosa, also known to heal with minimal
scarring, compared with dermal wounds [14]. Conversely,
TGFβ1a n dβ2 are elevated in adult wounds that heal with
a scar compared with embryonic wounds that heal without
as c a r[ 15]. The addition of TGFβ1 to a rat fetal wound that
would normally heal without a scar results in scar formation
[16], whereas in adult rats, scarring can be reduced by
the inhibition of TGFβ1o rT G F β2 using antibodies or the
addition of TGFβ3[17, 18]. Furthermore, mice embryos that
are genetically null for TGFβ3 heal with a scar in comparison
with wild-type littermates (with two normal copies of the
TGFβ3 genes), which exhibit scar-free healing [19].
Collectively,datafromtheseexperimentalmanipulations
suggest that TGFβ3 plays an important role in scar-free heal-
ing and that the application of this cytokine to adult wounds
may reduce the magnitude and accelerate the resolution of
the scarring response, resulting in a phenotype that more
closely resembles that of normal skin [3]( Figure 1).
3.2. Preclinical Studies Have Demonstrated the Eﬃcacy and
Safety of Avotermin (TGFβ3) for the Improvement of Scar
Appearance. An extensive, preclinical programme has inves-
tigated the feasibility of therapeutically manipulating the
scarring response using human recombinant TGFβ3, avoter-
min (Juvista: Renovo, UK) to improve the appearance of
scars [20]. This preclinical programme was facilitated by
the high level of amino acid homology between humans
and animals for TGFβ3 and the surface receptors through
which it exerts its biological eﬀects (TGFβ receptors type
I and type II). A standardised rat model was used to
investigate the eﬃcacy of avotermin for the improvement
of scarring. Intradermal injection of avotermin (50 and
100ng/100μL/linearcm) to cutaneous incisional wounds
signiﬁcantly reduced scarring compared with controls in
adult rats [18]. The macroscopic improvements in scarring
achieved with avotermin were accompanied by histolog-
ical improvements in the architecture of the neodermis,
including a more normal basket weave arrangement ofDermatology Research and Practice 3
Table 2: Agents in development for the reduction of dermal scarring.
Agents in preclinical development for the reduction of dermal scarring
Company Agent Status
First String polypeptide α-connexin Preclinical
Phylogica PYC-35B Preclinical
Sirnaomics STP-705 Preclinical
Agents in clinical development for the reduction of dermal scarring
Capstone Therapeutics AZX-100: 24 amino acid peptide analogue of heat shock protein 20, an
intracellular actin-relaxing molecule
Phase II
CoDa Therapeutics Nexagon: an anti-connexin oligonucleotide, shown to increase rate of
wound healing
Phase I
Excaliard antisense inhibitors of Smads, Connective Tissue Growth Factor Phase II
Renovo Ilodecakin (Prevascar): recombinant human interleukin 10 Phase II
Avotermin (Juvista): recombinant human TGFβ3 Phase III
Mechanism of action of avotermin (recombinant
human TGFβ3): overview
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Figure 1: Eﬀect of TGFβ3 on the duration and magnitude of the scar-forming healing response. There are typically three overlapping phases
involved in healing and scarring: inﬂammatory phase (blue), proliferative phase (pink), and deposition and remodelling phase (purple).
TGFβ3 reduces both the magnitude and the duration of each of the phases, resulting in a permanent change in tissue architecture such that
collagen within the dermis is arranged in a more “basket weave” orientation (b), unlike the closely packed, parallel bundles of collagen that
are characteristic of adult scar-forming healing (a). Consequently, the application of TGFβ3 to adult wounds results in a phenotype that
more closely resembles that of normal skin (c).4 Dermatology Research and Practice
collagen [2, 18, 19]. The rat model was also used to
optimise the dose, frequency, and formulation of avotermin,
demonstrating that two injections of avotermin (50 and
100ng/100μL/linearcm)administeredatthetimeofwound-
ing and 24 hours later, resulted in the greatest improve-
ments in scarring compared with controls. A comprehensive
preclinical safety program to support the development
of avotermin was also completed. Speciﬁc safety studies
in a clinically relevant pig model also demonstrated that
intradermal administration of avotermin, at concentrations
>12 times higher than those shown to be eﬃcacious in
people, is well tolerated, does not adversely aﬀect wound
healing or wound tensile strength, has low systemic bioavail-
ability and is rapidly cleared with no systemic toxicity
[21].
3.3. Avotermin is the First in a New Class of Prophylactic
Medicines in Clinical Development to Improve Scar Appear-
ance. Following encouraging eﬃcacy and safety data from
the preclinical studies, an extensive phase I/II clinical trial
programme was executed to evaluate the safety and optimise
both the administration of avotermin and the design of
clinical studies to assess its scar improving eﬀects.
The phase I/II trial programme included a series of
prospective, double-blind, within-subject placebo-control-
led, randomised clinical trials in human volunteers and
patients. A number of parameters that can inﬂuence the
appearance of scars (e.g. age, race, sex, anatomical location,
etc.) have been identiﬁed. To overcome scar variability due
to these parameters, a within-subject trial design, which
allowed the eﬀect of the drug to be compared with placebo
across anatomically matched pairs of scars, was used in
the phase I/II clinical programme. This within-subject
design controlled for genetic and environmental factors
aﬀecting wound healing and scarring between individuals.
By exploring a number of ways of assessing scars that
result from experimental wounds, robust endpoints for the
assessment of scarring have been developed and validated.
In addition to assessing standard, objective endpoints for
example, scar redness, pigmentation, width, height, volume,
surface area [22, 23], more holistic assessments of scars have
been developed. A visual analogue scale was used along
with scar ranking to assess scars either on the patients
(assessed by either the investigator or the patient themselves)
or using standardised digital images (assessed by panels of
clinicians/lay people). The visual analogue scale and scar
ranking assessments have been shown to be robust and
sensitive methods for accurately assessing dermal scarring
[24]. During the phase I/II programme, an improved scar
assessment tool was developed, the Global Scar Comparison
Scale (GSCS) speciﬁcally for use in within-subject controlled
trials. The GSCS incorporates the well-established principles
of a visual analogue scale, with the beneﬁts of scar ranking to
provide a more accurate and sensitive measure of treatment
eﬀect with clinical relevance. The scale allows assessors to
indicate which of two scars on the same subject is better
and by how much, and is eﬀectively a double VAS scale,
symmetrical around a zero point, with one end of the scale
used to indicate that one scar is better and the other end
of the scale used to indicate that the other scar is better.
The midpoint of the scale is used to indicate that there is
no diﬀerence between the two scars and scores further away
from the midpoint indicate a greater diﬀerence between two
scars. The GSCS is also a holistic assessment tool; assessors
areaskedtotakeallscarfeaturesintoconsiderationincluding
scar width, height, contour, and colour. Both the within-
patient design and use of the GSCS, which has now been
validated in a number of phase II studies, received favourable
feedback from the European Medicines Agency (EMEA)
and will be used to assess avotermin further in phase III
studies.
In all clinical studies, avotermin was administered
around the time of surgery as an intradermal injection either
along the planned line of incision or down both margins of a
closed wound, to direct delivery and ensure accurate dosing.
The data collected from more than 1,100 subjects who have
been exposed to avotermin during the extensive phase I/II
programme demonstrate that avotermin is well tolerated
with a favourable safety proﬁle. Furthermore, no adverse
eﬀects on normal healing have been reported. To date, seven
double-blind, placebo-controlled, prospective trials have
met their primary endpoint, demonstrating a statistically
signiﬁcant improvement in scarring with avotermin. (These
trials are registered with ClinicalTrials.gov: NCT00847925,
NCT00847795, NCT00432211, NCT00629811,
NCT00627536, NCT00594581, and NCT00430326.)
Intradermal avotermin has a broad eﬃcacious dose
range with doses of 50 to 500ng/100μL per linear cm of
wound margin, administered around the time of surgery,
signiﬁcantly improving scar appearance [25]( Figure 2).
Although eﬀective following a single application, optimal
eﬃcacy is achieved using a twice dosing regimen, the ﬁrst
dose given at the time of wounding and the second dose
24 hours later. The rationale for dosing at the time of
wounding is to inﬂuence the initial cascade of molecular and
cellular processes involved in wound healing and scarring
that are triggered immediately after wounding. A subsequent
administration, 24 hours later, has been shown to provide
further improvements in scarring compared with placebo,
which are apparent after only 6 weeks and are maintained
beyond one year [25]. Dosing schedules involving more than
two administrations have been assessed and found to be sub-
optimal due to potential injury caused by repeated injections
at the wound site and inconvenient due to multiple clinic
visits.
Although the majority of the phase II studies investigat-
ing the safety and eﬃcacy of avotermin have been conducted
in volunteers, two recent studies performed in patients
demonstrate that the improvements in scarring translate
to a clinical setting. Two double-blind, placebo-controlled,
randomised, phase II trials in patients demonstrated the
scar-improving eﬃcacy and safety of intradermal avotermin
administered at a dose of 500ng/100μL per linear cm of
wound margin on a single occasion following bilateral vari-
cose vein surgery, or administered at a dose of 200ng/100μL
p e rl i n e a rc mo fw o u n dm a r g i no nt w oo c c a s i o n s( i m m e -
diately after wound closure and 24 hours later) in patients
undergoing scar revision surgery (Figure 3). The mechanismDermatology Research and Practice 5
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Figure 2: Photographic images showing the improvement in scar
appearance with avotermin versus placebo and standard care.
Two patients (one with paler skin (b)) with wounds treated with
avotermin 200ng/100μl/linearcm of wound margin immediately
before surgery and 24 hours later (i), placebo (ii), and standard care
(iii) at Month 12.
of action associated with the macroscopic beneﬁts in scar-
ring reported by assessment panels, investigators, and the
patients undergoing scar revision surgery in this study was
conﬁrmed by histological improvements in the architecture
of the scars, with improved epidermal restitution and an
organisation of the extracellular matrix of the papillary
and reticular dermis which more closely resembles normal
skin.
Key learnings from the extensive phase I/II clinical trial
programme have been used to optimise the design of a
phase III study to further evaluate the potential beneﬁts of
administering avotermin to improve scar appearance (Clin-
icalTrial.gov NCT00742443). This study is a randomised
double-blind, within-patient, placebo-controlled trial to
investigate the eﬃcacy of avotermin in conjunction with scar
revision surgery for the improvement of disﬁguring scars.
The eﬀects of avotermin, administered immediately after
wounding and 24 hours later, on subsequent scar formation
will be assessed by an independent clinical scar assessment
panel. The panel will assess digital photographs of scars
at 12 months after surgery using the GSCS. The trial is
currently under way in patients with disﬁguring linear scars
that are suitable for revision and data are awaited with
interest.
ii i
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Figure 3: Photographic images showing the improvements in
scarring following scar revision surgery with avotermin versus
placebo at Month 7 (a) and Month 12 (b). Sections of mature
linear scars were randomised to receive placebo (i) or avotermin
200ng/100μL (ii) per linear cm immediately following wound
closure and 24 hours later.
4. Conclusions and Perspectives
As many patients suﬀer physical and psychological trauma
as a result of scarring, there is a medical need for a
prophylactic therapy given at the time of surgery to improve
the appearance of scars. Current treatments for scarring
have limited eﬃcacy and are not supported by data from
prospective, robust clinical trials. Consequently there is no
well-established standard of care and the management of
scarring is often inadequate. While a number of biological
agents designed to manipulate the scarring process are in
development, avotermin is the most advanced in phase
III clinical trials for the improvement of scar appearance
following scar revision surgery. An extensive preclinical and
clinical programme has shown that avotermin promotes the
regeneration of normal skin and improves scar appearance.
The ongoing phase III programme is designed to show that
avotermin supplements good surgical technique, resulting
in less noticeable scars that more closely resemble the
surrounding skin following scar revision surgery.
Avotermin is the ﬁrst in a new class of prophylactic
therapeuticsindevelopmentfortheimprovementofscarring6 Dermatology Research and Practice
and could have a signiﬁcant impact on the outcome of
scarring for patients in the future.
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